• About us
  • Management Team
  • Advisory Board
  • Investors
• Business
  • Markets
  • Partners
• Technology
  • Discovery
  • Library Generation
  • Assay Development & Screening
    • Confocal Fluorimetry
  • Intellectual Property
• Applications
  • Protein Engineering
    • Protease
  • Strain Development
    • Developing a Lactic acid strain
  • Process Development
    • Fermentation
    • Downstream Processing
• Products
  • Mannanase
    • Animal Feed
    • Food processing
  • Cellulases
    • Hydrolysis od Spruce
• Press Room
  • Events
  • Publications
• Career
  • Scientist Chemistry (m/f)
  • Scientist Biochemistry (m/f)
• Contact
  • Map
  • Directions

30 April 2010

Change in Leadership at DIREVO Industrial Biotechnology GmbH

DIREVO Industrial Biotechnology GmbH (Direvo) announced today that effective May 1st Dr. Jorg Riesmeier was promoted to Chief Executive Officer. Dr. Riesmeier who joined on January 15, 2010 as Chief Operating Officer is succeeding Dr. Thomas von Rüden who advocated the change in leadership. Dr. von Rüden will continue to serve the company as an advisor.
Dr. Karl-Gerhard Seifert, chairman of the company’s advisory board commented: “After having set up the technology platform and the recent closing of the series A financing Dr. von Rüden felt that this is the right point to hand over leadership of the company to Dr. Riesmeier. Dr. Riesmeier will lead the company to the next level of becoming a product development company. Dr. von Rüden will continue to support Direvo as an advisor. The Shareholders and the Advisory Board thank Dr. von Rüden for his effort and commitment which again secured major progress and success for Direvo“.
“I thank the Board for the appointment and Thomas very much for all his efforts and dedication to make Direvo a widely recognized technology leader. Our company is in a great shape and I am looking forward to guide the company towards a strong product orientation”, said Jorg Riesmeier.


About DIREVO Industrial Biotechnology GmbH

DIREVO Industrial Biotechnology GmbH (“DIREVO”) can look back on a successful ten-year track record in protein optimization. Initially a business unit of DIREVO Biotech AG, it became an independent company in 2008 in the course of the sale of DIREVO Biotech AG to Bayer Healthcare AG. DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform.

Initial products from DIREVO´s enzyme optimization facility have already gone on the market. DIREVO’s multi-parameter optimized Phytase (in collaboration with Genencor) and Mannanase (proprietary) are best-in-class products.

DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include TVM Capital (Munich), NRW Bank (Düsseldorf), Wölbern Private Equity Partner GmbH (Hamburg), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), Mulligan BioCapital (Hamburg), SandersMorrisHarris EnzymesLLC (New York), Danisco A/S (Copenhagen), and several private investors.

print page